Background. Alzheimer's disease (AD) is the most common form of dementia and its clinical differentiation from fronto-temporal dementia (FTD) is often difficult. Cerebro-spinal fluid (CSF) Tau, p-Tau and β amyloid 1-42 (βA 1-42) concentrations seem to be a valid support in clinical diagnosis. Our goal is to analyse the CSF Tau, p-Tau e βA 1-42 concentrations and their ratio to identify early-onset AD from subjects with FTD. Methods. 82 CSF samples collected with lumbar puncture: 43 from subjects with probable AD (NINCDS-ADRA criteria) and 39 from subjects with probable FTD (Neary criteria). Tau, p-Tau and βA 1-42 concentrations have been tested with ELISA test (Innotest, Innogenetics, Ghent, Belgium). Results. Only βA 1-42 and p-Tau concentrations have shown statistically significant differences between AD and FTD subjects (βA 1-42 AD: 383±169 ng/L, FTD: 510±288 ng/L, p=0.05 and p-Tau AD: 92±45 ng/L, FTD: 70±46 ng/L, p=0.002). The graphic combination of Tau, p-Tau e βA 1-42 has confirmed the clinical suspect of AD in 34/43 samples (sensitivity: 79%, specificity: 69%). FTD clinical suspect has been confirmed in 19/39 samples (sensitivity: 49%, specificity: 88%). Our data indicate the ratio βA 1-42/Tau and βA 1-42/pTau as clinically significant to discriminate AD from FTD (p=0.002 and p1-42 concentrations and their ratio, although tested on a small number of samples, seems to be a further support to assist clinician in confirming a suspected AD or to exclude AD in a case of clinical suspect of FTD.
|Translated title of the contribution||Tau, p-Tau and beta amiloid 1-42 concentrations in Alzheimer and frontotemporal dementia patients|
|Number of pages||5|
|Journal||Rivista Italiana della Medicina di Laboratorio|
|Publication status||Published - 2008|
ASJC Scopus subject areas
- Biochemistry, medical
- Medical Laboratory Technology